Helper virus-free gutless adenovirus (HF-GLAd): a new platform for gene therapy

키워드

참고문헌 (99)

1. Blaese RM, "T lymphocyte-directed gene therapy for ADA-SCID : initial trial results after 4 years", Science, 270, pp.475~480 (1995)
2. Bordignon C, "Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients", Science, 270, pp.470~475 (1995)
3. Kohn DB, "Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency", Nat Med, 1, pp.1017~1023 (1995)
4. Yla-Herttuala S, "Endgame : glybera finally recommended for approval as the first gene therapy drug in the European union", Mol Ther, 20, pp.1831~1832 (2012)
5. Darrow JJ, "Luxturna : FDA documents reveal the value of a costly gene therapy", Drug Discov Today, 24, pp.949~954 (2019)
6. Mahajan R, "Onasemnogene abeparvovec for spinal muscular atrophy : the costlier drug ever", Int J Appl Basic Med Res, 9, pp.127~128 (2019)
7. Lee CS, "Adenovirusmediated gene delivery : potential applications for gene and cell-based therapies in the new era of personalized medicine", Genes Dis, 4, pp.43~63 (2017)
8. Rowe WP, "Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture", Proc Soc Exp Biol Med, 84, pp.570~573 (1953)
9. Hilleman MR, "Recovery of new agent from patients with acute respiratory illness", Proc Soc Exp Biol Med, 85, pp.183~188 (1954)
10. Crystal RG, "Adenovirus : the first effective in vivo gene delivery vector", Hum Gene Ther, 25, pp.3~11 (2014)
11. Gaynor RB, "Cis-acting induction of adenovirus transcription", Cell, 33, pp.683~693 (1983)
12. Lichtenstein DL, "Functions and mechanisms of action of the adenovirus E3 proteins", Int Rev Immunol, 23, pp.75~111 (2004)
13. Graham FL, "Characteristics of a human cell line transformed by DNA from human adenovirus type 5", J Gen Virol, 36, pp.59~74 (1977)
14. Louis N, "Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line", Virology, 233, pp.423~429 (1997)
15. Murakami P, "A single short stretch of homology between adenoviral vector and packaging cell line can give rise to cytopathic effect-inducing, helper-dependent E1-positive particles", Hum Gene Ther, 13, pp.909~920 (2002)
16. Lochmuller H, "Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants(delta E1 + delta E3)during multiple passages in 293 cells", Hum Gene Ther, 5, pp.1485~1491 (1994)
17. Smith JG, "Molecular characterization of an adenoviral vector resulting from both homologous and nonhomologous recombination", Cancer Gene Ther, 6, pp.475~481 (1999)
18. Simek S, "FDA Perspectives on the use of the adenovirus reference material", BioProcess J, 1, pp.40~42 (2002)
19. Fallaux FJ, "New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses", Hum Gene Ther, 9, pp.1909~1917 (1998)
20. Imperiale MJ, "Common control of the heat shock gene and early adenovirus genes : evidence for a cellular E1A-like activity", Mol Cell Biol, 4, pp.867~874 (1984)
21. Lozier JN, "Toxicity of a first-generation adenoviral vector in rhesus macaques", Hum Gene Ther, 13, pp.113~124 (2002)
22. Jiang H, "Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination", Cancer Res, 77, pp.3894~3907 (2017)
23. Swaminathan S, "Regulation of adenovirus E2 transcription unit; in the molecular repertoire of adenoviruses III: biology and pathogenesis", pp.177~194 (1995), Springer Berlin Heidelberg
24. Evans JD, "Distinct roles of the adenovirus E4 ORF3 protein in viral DNA replication and inhibition of genome concatenation", J Virol, 77, pp.5295~5304 (2003)
25. O’Neal WK, "Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery", Hum Gene Ther, 9, pp.1587~1598 (1998)
26. Jozkowicz A, "Gutless adenoviral vectors-promising tools for gene therapy", European Surgery-Acta Chirurgica Austriaca, 34, pp.95~100 (2002)
27. Bett AJ, "Packaging capacity and stability of human adenovirus type 5 vectors", J Virol, 67, pp.5911~5921 (1993)
28. Alemany R, "Complementation of helper-dependent adenoviral vectors : size effects and titer fluctuations", J Virol Methods, 68, pp.147~159 (1997)
29. Parks RJ, "A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging", J Virol, 71, pp.3293~3298 (1997)
30. Parks RJ, "Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors", J Virol, 73, pp.8027~8034 (1999)
31. Schiedner G, "Variables affecting in vivo performance of high-capacity adenovirus vectors", J Virol, 76, pp.1600~1609 (2002)
32. Sandig V, "Optimization of the helper-dependent adenovirus system for production and potency in vivo", Proc Natl Acad Sci U S A, 97, pp.1002~1007 (2000)
33. Parks RJ, "A helper-dependent adenovirus vector system : removal of helper virus by Cre-mediated excision of the viral packaging signal", Proc Natl Acad Sci U S A, 93, pp.13565~13570 (1996)
34. Palmer D, "Improved system for helperdependent adenoviral vector production", Mol Ther, 8, pp.846~852 (2003)
35. Jager L, "A rapid protocol for construction and production of high-capacity adenoviral vectors", Nat Protoc, 4, pp.547~564 (2009)
36. Su Q, "Purification of the recombinant adenovirus by cesium chloride gradient centrifugation", Cold Spring Harb Protoc, pp.095547~ (2019)
37. Ng P, "Development of a FLP", frt system for generating helper-dependent adenoviral vectors, 2001, pp.3, 809~815
38. Cheshenko N, "A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus", Gene Ther, 8, pp.846~854 (2001)
39. Kubo S, "An HSV amplicon-based helper system for helper-dependent adenoviral vectors", Biochem Biophys Res Commun, 307, pp.826~830 (2003)
40. Dongwoo Lee, "No more helper adenovirus: production of gutless adenovirus (GLAd) free of adenovirus and replication-competent adenovirus (RCA) contaminants", Experimental and Molecular Medicine, 51, pp.1~18 (2019), 생화학분자생물학회[DOI]
41. Wu N, "Overexpression of Ad5 precursor terminal protein accelerates recombinant adenovirus packaging and amplification in HEK-293 packaging cells", Gene Ther, 21, pp.629~637 (2014)
42. Stemmler MP, "E-cadherin intron 2 contains cis-regulatory elements essential for gene expression", Development, 132, pp.965~976 (2005)
43. Harraghy N, "Sustained transgene expression using MAR elements", Curr Gene Ther, 8, pp.353~366 (2008)
44. Suzuki M, "Large-scale production of high-quality helperdependent adenoviral vectors using adherent cells in cell factories", Hum Gene Ther, 21, pp.120~126 (2010)
45. Smaill F, "A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity", Sci Transl Med, 5, pp.205ra134~ (2013)
46. McElrath MJ, "HIV-1vaccine-induced immunity in the test-of-concept Step Study : a case-cohort analysis", Lancet, 372, pp.1894~1905 (2008)
47. Harro C, "Safety and immunogenicity of the Merck adenovirus serotype 5(MRKAd5)and MRKAd6 human immunodeficiency virus type 1trigene vaccines alone and in combination in healthy adults", Clin Vaccine Immunol, 16, pp.1285~1292 (2009)
48. Mennechet FJ, "Ebola virus vaccine : benefit and risks of adenovirus-based vectors", Expert Rev Vaccines, 14, pp.1471~1478 (2015)
49. Green CA, "Chimpanzee adenovirus-and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults", Sci Transl Med, 7, pp.300ra126~ (2015)
50. Scallan CD, "An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models", Clin Vaccine Immunol, 20, pp.85~94 (2013)
51. Alemany R, "Oncolytic adenoviruses in cancer treatment", Biomedicines, 2, pp.36~49 (2014)
52. Huang H, "Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy", Nat Commun, 10, pp.4801~ (2019)
53. Yamamoto M, "Current issues and future directions of oncolytic adenoviruses", Mol Ther, 18, pp.243~250 (2010)
54. Brunetti-Pierri N, "Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates", Hum Gene Ther, 15, pp.35~46 (2004)
55. Schnell MA, "Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors", Mol Ther, 3, pp.708~722 (2001)
56. Basner-Tschakarjan E, "Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production", J Gene Med, 8, pp.1300~1306 (2006)
57. Hartman ZC, "Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo", J Virol, 81, pp.1796~1812 (2007)
58. Worgall S, "Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration", Hum Gene Ther, 8, pp.37~44 (1997)
59. Xiang ZQ, "A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier", Virology, 219, pp.220~227 (1996)
60. Kafri T, "Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression : implications for gene therapy", Proc Natl Acad Sci U S A, 95, pp.11377~11382 (1998)
61. Molinier-Frenkel V, "Immune response to recombinant adenovirus in humans : capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes", J Virol, 74, pp.7678~7682 (2000)
62. Zhong L, "Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells", European Journal of Immunology, 29, pp.964~972 (1999)
63. Fausther-Bovendo H, "Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what’s important?", Hum Vaccin Immunother, 10, pp.2875~2884 (2014)
64. Smith JG, "Neutralizing antibody blocks adenovirus infection by arresting microtubule-dependent cytoplasmic transport", J Virol, 82, pp.6492~6500 (2008)
65. Parker AL, "Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer", J Virol, 83, pp.479~483 (2009)
66. Pichla-Gollon SL, "Effect of preexisting immunity on an adenovirus vaccine vector : in vitro neutralization assays fail to predict inhibition by antiviral antibody in vivo", J Virol, 83, pp.5567~5573 (2009)
67. Calcedo R, "Class I-restricted T-cell responses to a polymorphic peptide in a gene therapy clinical trial for alpha-1-antitrypsin deficiency", Proc Natl Acad Sci U S A, 114, pp.1655~1659 (2017)
68. Muruve DA, "Helperdependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo", J Virol, 78, pp.5966~5972 (2004)
69. Alzuguren P, "Transient depletion of specific immune cell populations to improve adenovirus-mediated transgene expression in the liver", Liver Int, 35, pp.1274~1289 (2015)
70. Dai Y, "Cellular and humoral immune responses to adenoviral vectors containing factor IX gene : tolerization of factor IX and vector antigens allows for long-term expression", Proc Natl Acad Sci U S A, 92, pp.1401~1405 (1995)
71. Kaplan JM, "Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung", Hum Gene Ther, 8, pp.1095~1104 (1997)
72. Otake K, "Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses", Hum Gene Ther, 9, pp.2207~2222 (1998)
73. Engelhardt JF, "Adenovirusmediated transfer of the CFTR gene to lung of nonhuman primates : biological efficacy study", Hum Gene Ther, 4, pp.759~769 (1993)
74. Chillon M, "Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro", Gene Ther, 5, pp.995~1002 (1998)
75. Croyle MA, ""Stealth"adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung", J Virol, 75, pp.4792~4801 (2001)
76. Benhar I, "The privileged immunity of immune privileged organs : the case of the eye", Front Immunol, 3, pp.296~ (2012)
77. Galea I, "What is immune privilege (not)?", Trends Immunol, 28, pp.12~18 (2007)
78. Alliegro M, "Low-dose gene therapy reduces the frequency of enzyme replacement therapy in a mouse model of lysosomal storage disease", Mol Ther, 24, pp.2054~2063 (2016)
79. Marshall E, "Gene therapy death prompts review of adenovirus vector", Science, 286, pp.2244~2245 (1999)
80. Naso MF, "Adeno-associated virus(AAV)as a vector for gene therapy", BioDrugs, 31, pp.317~334 (2017)
81. Wang D, "Adeno-associated virus vector as a platform for gene therapy delivery", Nat Rev Drug Discov, 18, pp.358~378 (2019)
82. Armbruster N, "Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy", Mol Ther Methods Clin Dev, 3, pp.16060~ (2016)
83. George LA, "Hemophilia B gene therapy with a high-specific-activity factor IX variant", N Engl J Med, 377, pp.2215~2227 (2017)
84. Pierce EA, "The status of RPE65 gene therapy trials : safety and efficacy", Cold Spring Harb Perspect Med, 5, pp.a017285~ (2015)
85. Duan D, "Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy", Mol Ther, 26, pp.2337~2356 (2018)
86. Kharraz Y, "Understanding the process of fibrosis in Duchenne muscular dystrophy", Biomed Res Int, 2014, pp.965631~ (2014)
87. Dudley RW, "Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector", Hum Gene Ther, 15, pp.145~156 (2004)
88. Gilbert R, "Dystrophin expression in muscle following gene transfer with a fully deleted (“gutted”) adenovirus is markedly improved by trans-acting adenoviral gene products", Hum Gene Ther, 12, pp.1741~1755 (2001)
89. Bates GP, "Huntington disease", Nat Rev Dis Primers, 1, pp.15005~ (2015)
90. den Hollander AI, "Mutations in the CEP290(NPHP6)gene are a frequent cause of Leber congenital amaurosis", Am J Hum Genet, 79, pp.556~561 (2006)
91. Lee W, "Complex inheritance of ABCA4 disease : four mutations in a family with multiple macular phenotypes", Hum Genet, 135, pp.9~19 (2016)
92. Tsybovsky Y, "The ATP-binding cassette transporter ABCA4 : structural and functional properties and role in retinal disease", Adv Exp Med Biol, 703, pp.105~125 (2010)
93. Guse K, "160. Gene therapy for stargardt disease using helper-dependent adenoviral vectors", Mol Ther, 20, pp.S64~ (2012)
94. McGuigan DB, "EYS mutations causing autosomal recessive retinitis pigmentosa : changes of retinal structure and function with disease progression", Genes (Basel), 8, pp.178~ (2017)
95. Pierrache LH, "Visual prognosis in USH2A-associated retinitis pigmentosa is worse for patients with usher syndrome type iia than for those with nonsyndromic retinitis pigmentosa", Ophthalmology, 123, pp.1151~1160 (2016)
96. Sun M, "Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson’s disease", Hum Gene Ther, 15, pp.1177~1196 (2004)
97. Axelsen TM, "Gene therapy for Parkinson’s disease, an update", J Parkinsons Dis, 8, pp.195~215 (2018)
98. Nilsson P, "Gene therapy in Alzheimer’s disease-potential for disease modification", J Cell Mol Med, 14, pp.741~757 (2010)
99. Hammerich L, "Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination", Nat Med, 25, pp.814~824 (2019)

관련 논문AI추천